Ignite Creation Date:
2025-12-25 @ 3:25 AM
Ignite Modification Date:
2026-02-02 @ 12:05 AM
Study NCT ID:
NCT02787005
Status:
COMPLETED
Last Update Posted:
2024-11-21
First Post:
2016-05-26
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-07-01
Start Date Type:
ACTUAL
Primary Completion Date:
2022-02-28
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-02-28
Completion Date Type:
ACTUAL
First Submit Date:
2016-05-26
First Submit QC Date:
None
Study First Post Date:
2016-06-01
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2023-02-23
Results First Submit QC Date:
None
Results First Post Date:
2023-03-24
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-11-05
Last Update Post Date:
2024-11-21
Last Update Post Date Type:
ACTUAL